close
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

IQVIA Holdings, Inc. Common Stock (NY:IQV)

198.17 -4.83 (-2.38%)
Official Closing Price Updated: 6:30 PM EDT, Oct 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about IQVIA Holdings, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
IQVIA celebrates Marie E. Lamont and Dr. Joanne Hackett, winners of Healthcare Businesswomen's Association Awards
From IQVIA
Via Business Wire
Beyond The Numbers: 12 Analysts Discuss IQVIA Hldgs Stock
 
Via Benzinga
Get insights into the top movers in the S&P500 index of Friday's pre-market session.
Get insights into the top gainers and losers in the S&P500 index of Friday's pre-market session. 
Via Chartmill
3 Healthcare Stocks That Concern Us
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,... 
Via StockStory
Topics Stocks
IQVIA named a front-runner in generative AI innovation by global industry research and analysis firm
From IQVIA
Via Business Wire
IQVIA to Announce First-Quarter 2025 Results on May 6, 2025
From IQVIA
Via Business Wire
Stabilization and improvement seen in multiple key biopharma R&D metrics, says IQVIA Institute Report
From IQVIA Holdings Inc.
Via Business Wire
Alphabet To $185? Here Are 10 Top Analyst Forecasts For Thursday
 
Via Benzinga
These S&P500 stocks have an unusual volume in today's session
Curious about which S&P500 stocks are generating unusual volume on Wednesday? Find out below. 
Via Chartmill
These S&P500 stocks are gapping in today's session
Stay updated with the S&P500 gap up and gap down stocks on Wednesday. Get a glimpse of the market's movement during today's session. 
Via Chartmill
What's going on in today's session: S&P500 gap up and gap down stocks
Curious about the market action on Monday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session. 
Via Chartmill
Winners And Losers Of Q4: IQVIA (NYSE:IQV) Vs The Rest Of The Drug Development Inputs & Services Stocks
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how IQVIA (NYSE:IQV) and the rest... 
Via StockStory
Unpacking Q4 Earnings: West Pharmaceutical Services (NYSE:WST) In The Context Of Other Drug Development Inputs & Services Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at West Pharmaceutical Services (NYSE:WST) and its peers. 
Via StockStory
3 Reasons IQV is Risky and 1 Stock to Buy Instead
IQVIA’s stock price has taken a beating over the past six months, shedding 22.2% of its value and falling to $190.42 per share. This may have investors wondering how to approach the situation. 
Via StockStory
Drug Development Inputs & Services Stocks Q4 Results: Benchmarking Fortrea (NASDAQ:FTRE)
Let’s dig into the relative performance of Fortrea (NASDAQ:FTRE) and its peers as we unravel the now-completed Q4 drug development inputs & services earnings season. 
Via StockStory
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services industry, including Repligen (NASDAQ:RGEN) and... 
Via StockStory
IQVIA recognized as a leader in IDC MarketScape’s 2024 assessment for decentralized clinical trial technologies and consulting services
From IQVIA
Via Business Wire
Spotting Winners: Charles River Laboratories (NYSE:CRL) And Drug Development Inputs & Services Stocks In Q4
Looking back on drug development inputs & services stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Charles River Laboratories (NYSE:CRL) and its peers. 
Via StockStory
IQVIA Laboratories launches Site Lab Navigator with breakthrough e-Requisition innovation to transform clinical trials
From IQVIA
Via Business Wire
Dan Loeb Adjusts Healthcare Holdings: Danaher Stake Trimmed As Thermo Fisher Gains Favor
Loeb's Third Point LLC restructured their portfolio in last quarter of 2024. They decreased stake in Danaher Corp. and acquired stake in Thermo Fisher. 
Via Benzinga
IQVIA AI Assistant wins 2024 PM360 Innovation Award for Artificial Intelligence
From IQVIA
Via Business Wire
IQVIA CFO Ron Bruehlman to Speak at the TD Cowen Annual Health Care Conference on March 4, 2025
From IQVIA
Via Business Wire
IQVIA Releases 2024 Sustainability Report
From IQVIA
Via Business Wire
Earnings To Watch: Charles River Laboratories (CRL) Reports Q4 Results Tomorrow
Lab services company Charles River Laboratories (NYSE:CRL) will be reporting earnings tomorrow before the bell. Here’s what investors should know. 
Via StockStory
West Pharmaceutical Services (WST) Q4 Earnings Report Preview: What To Look For
Healthcare products company West Pharmaceutical Services (NYSE:WST) will be reporting earnings tomorrow morning. Here’s what to look for. 
Via StockStory
Medpace (MEDP) To Report Earnings Tomorrow: Here Is What To Expect
Clinical research company Medpace Holdings (NASDAQ:MEDP) will be announcing earnings results tomorrow after market hours. Here’s what to expect. 
Via StockStory
Stocks Edge Higher, Bank Giants Rally, Palantir Skyrockets: What's Driving Markets Thursday?
It's a mixed session on Wall Street, with major indices struggling for direction as investors hold their breath ahead of a key jobs report set for Friday morning. The S&P 500 and the Nasdaq 100 edged... 
Via Benzinga
Topics Stocks
IQVIA Delivers Solid Q4 Growth Despite 'Choppy' Market Conditions
IQVIA reaffirms its 2025 outlook, projecting up to $16.13 billion in revenue and EPS of $11.70-$12.10. Strong TAS growth and solid R&DS bookings fuel confidence. 
Via Benzinga
Gapping S&P500 stocks in Thursday's session
Stay updated with the S&P500 gap up and gap down stocks on Thursday. Get a glimpse of the market's movement during today's session. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Starting at $3.75/week.

Subscribe Today